Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

The molecular profiling and prognostic value of Chinese gastric signet ring cell carcinoma patients

Date

29 Sep 2019

Session

Poster Display session 2

Presenters

Jia Wei

Citation

Annals of Oncology (2019) 30 (suppl_5): v253-v324. 10.1093/annonc/mdz247

Authors

J. Wei1, Y. wang2, L. Liu3, C. Qiao4, J. Hu4, W. Wang5, J. Wang5, M. Yao6, K. Wang7, B. Liu1, S. Cui8

Author affiliations

  • 1 Oncology, The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, China, 210008 - Nanjing/CN
  • 2 Oncology, The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, China, 210029 - nanjing/CN
  • 3 Oncology, Jiangsu province hospital The first affiliated hospital of Nanjing medical university, 210004 - Nanjing/CN
  • 4 Department Of Clinical Interpretation, OrigiMed, 201100 - Shanghai/CN
  • 5 Department Of Cancer Immunology, OrigiMed, 201100 - Shanghai/CN
  • 6 Medical Department, OrigiMed, 201100 - Shanghai/CN
  • 7 Bioinformatics, OrigiMed, 200135 - Shanghai/CN
  • 8 Oncology, The first affiliated hospital of Nanjing medical university, 210029 - Nanjing/CN
More

Resources

Abstract 4989

Background

Gastric cancer (GC) is one of the most common lethal malignancies worldwide. Signet ring cell carcinoma (SRCC) is a poorly differentiated gastric cancer. The molecular characteristics and prognostic of SRCC are not well studied.

Methods

Formalin fixed paraffin embedded (FFPE) samples of 64 Chinese solid tumor patients were collected for next‐generation sequencing (NGS) based 450 genes panel assay. Genomic alterations including single base substitution, short and long insertions/deletions, copy number variations, gene fusions and rearrangement were assessed. Microsatellite stable (MSS) status and TMB (tumor mutational burden) were also acquired by an NGS algorithm.

Results

A total of 64 patients were identified as GC-SRCC through SRCC histology. The most frequently mutated genes were TP53(48%), CDH1(31%), ARID1A(14%), CDKN2A(9%), LRP1B(9%), KMT2D(6%), NF1(6%), ERBB2(9%) and GLI3(8%). Meanwhile, the copy numbers of FGFR2(14%), FGF3(8%), FGF19(8%), FGF4(8%), MYC(8%), CCND1(6%) and CDKN2A(9%) were frequently altered in SRCC.FGFR2 and 11q13 amplification is the first time reported in Chinese SRCC. Moreover, FGFR2 rearrangement (FGFR2/VTI1A and FGFR2/TACC2) was detected in 4% tumor samples. 34 cases had received chemotherapy, 4 cases had confirmed partial responses (PR); 14 cases had reached the stability of disease (SD). Noticeably, patients harboring gene rearrangement (N = 9) were observed a much shorter overall survival time (OS) in comparison with patients without any gene rearrangement (N = 14) (13.2 months vs 24.2 months, P < 0.05). Additionally, patients with CDH1 mutation (N = 9) showed a shorter OS than CDH1 wide type (N = 25) (14.2 months vs 25.3 months, P = 0.11), although the difference was not statistically significant.

Conclusions

Our observation reveals the molecular characteristics of SRCC. Gene rearrangements might associate to shorter OS. FGFR2 and 11q13 region amplification were newly observed in SRCC. It might provide new possibilities for the treatment of SRCC. Due to the limitations of the number of samples, the results may require further research and validation.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings